Search results
31 sie 2023 · We report the design and baseline data for FLOW (NCT03819153), a trial investigating the effects of semaglutide, a once-weekly (OW) GLP-1RA, on kidney outcomes in participants with CKD and T2D. Methods: FLOW is a randomised, double-blind, parallel-group, multinational, phase 3b trial.
18 sty 2023 · FLOW is a dedicated kidney outcomes trial designed to assess the kidney-protective effects of semaglutide, a GLP-1RA, and its potential to improve treatment options in people with CKD and T2D. The composite endpoint components selected for FLOW are widely recognised by health authorities and regulatory bodies as robust measures for the ...
24 cze 2024 · FLOW trial participants with type 2 diabetes and chronic kidney disease were stratified by baseline SGLT2i use (N = 550) or no use (N = 2,983) and randomized to semaglutide/placebo.
30 sie 2024 · The FLOW trial showed that among patients with CKD and DM2, once weekly subcutaneous semaglutide was superior to placebo in improving renal and CV outcomes over a median follow-up of 3.4 years.
29 lip 2024 · The FLOW study now provides unequivocal evidence of kidney protective effects with semaglutide in adults with type 2 diabetes mellitus and chronic kidney disease.
10 lip 2024 · The FLOW (Evaluate Renal F unction with Semag l utide O nce W eekly) study is a company-funded, randomized, double-blind, placebo-controlled, event-driven, superiority trial, assessing the efficacy and safety of the glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide, on renal outcomes in patients with type 2 diabetes (T2D) and chronic...
